Cargando…

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation

Atherosclerosis is a basic pathological characteristic of many cardiovascular diseases, and if not effectively treated, patients with such disease may progress to atherosclerotic cardiovascular diseases (ASCVDs) and even heart failure. The level of plasma proprotein convertase subtilisin/kexin type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Minglu, Hou, Chang, Liu, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036592/ https://www.ncbi.nlm.nih.gov/pubmed/36970356 http://dx.doi.org/10.3389/fcvm.2023.1148486

Ejemplares similares

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
por: Wang, Kexin, et al.
Publicado: (2022)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
por: van Solingen, Coen, et al.
Publicado: (2021)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease
por: Smeets, Diede, et al.
Publicado: (2022)

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Association Between Periodontal Disease and Atherosclerotic Cardiovascular Diseases: Revisited
por: Zardawi, Faraedon, et al.
Publicado: (2021)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial
por: Xia, Jiachun, et al.
Publicado: (2022)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

Paeonol for the Treatment of Atherosclerotic Cardiovascular Disease: A Pharmacological and Mechanistic Overview
por: Wu, Min, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
por: Finney, Alexandra C., et al.
Publicado: (2023)

Common variable immunodeficiency—an independent risk factor for atherosclerotic cardiovascular diseases
por: Mattila, Juho, et al.
Publicado: (2023)

PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review
por: Lv, Pinchao, et al.
Publicado: (2022)

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects
por: Li, Yan-yan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
por: Inno, Alessandro, et al.
Publicado: (2021)

Prevalence, awareness, treatment, and risk factor control of high atherosclerotic cardiovascular disease risk in Guangzhou, China
por: Liu, Hui, et al.
Publicado: (2023)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor
por: Nahmias, Avital, et al.
Publicado: (2020)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options
por: Maisch, Bernhard
Publicado: (2019)

Comprehensive Analysis of the Immune Infiltrates and Aberrant Pathways Activation in Atherosclerotic Plaque
por: Han, Hukui, et al.
Publicado: (2021)

Editorial: Immune and autoimmune mechanisms in cardiovascular disease
por: Winkels, Holger, et al.
Publicado: (2023)

Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
por: Louloudis, Georgios, et al.
Publicado: (2021)

The effect of telemedicine on secondary prevention of atherosclerotic cardiovascular disease: A systematic review and meta-analysis
por: Deng, Liangying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oo4a05fttebhs8bogr4op55u1e